Generation Bio Co 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Generation Bio Co 's ROA in the third quarter of 2025?
Generation Bio Co recorded a cumulative net loss of $-63 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -34.42%.

However, within the Healthcare sector 472 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 3830, from total ROA ranking in the second quarter of 2025 at 3849.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	-51.15 %	-32.6 %	-30.11 %	-37.26 %	-34.77 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-63	-72	-72	-132	-145
Return On Assets (TTM)	-34.42 %	-33.93 %	-30.61 %	-51.34 %	-50.05 %
GBIO's Total Ranking	# 3830	# 3849	# 3856	# 4828	# 4247
Total Assets (TTM) in million	120	178	200	230	246
Seq. Total Assets Change	-32.33 %	-10.9 %	-13.31 %	-6.54 %	-6.63 %
Seq. Net Income Change	-	-	-	-	-

GBIO's 5 Years Annual ROA >> Back to GBIO Management Effectiveness >> Compare GBIO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 193
Sector	# 473
Overall	# 3784

Return On Assets Statistics
High	Average	Low
-7.05 %	-32.91 %	-51.08 %
(Mar 31 2021)		(Dec 31 2024)

Financial Statements
Generation Bio Co 's Assets	$ 120 million	GBIO's Balance sheet
Generation Bio Co 's Income	$ -6 million	Quarterly GBIO's Income Statement
GBIO's Income by Division		See GBIO's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-37.93 %	-0.22 %	-21.35 %	60.81 %	-
Total Assets in million	230	371	372	473	294
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-132	-127	-137	-119	-81
Annual Return On Assets	-57.2 %	-34.14 %	-36.76 %	-25.22 %	-27.4 %

GBIO's 5 Years Annual ROA >> Back to GBIO Management Effectiveness >> Compare GBIO ROA to its Competitors

More Return On Assets Ratios
GBIO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GBIO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GBIO's Competitors
Subscribers only: Roa for Generation Bio Co 's Suppliers
Subscribers only: Return On Assets for GBIO's Customers

You may also want to know
GBIO's Roi	GBIO's Inventory Turnover Ratio	GBIO's Growth Rates	GBIO's Dividend Comparisons
	GBIO's Profitability Ratios	GBIO's Asset Turnover Ratio	GBIO's Dividend Growth
GBIO's Roe	GBIO's Valuation Ratios	GBIO's Financial Strength Ratios	GBIO's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.